Cytokinetics (CYTK) Enterprise Value (2010 - 2026)

Cytokinetics (CYTK) has reported Enterprise Value for 17 consecutive years, with -$818.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value rose 12.79% year-over-year to -$818.6 million; the TTM figure through Mar 2026 stood at -$818.6 million (up 12.79% YoY), while the FY2025 annual figure was -$882.2 million, up 18.04% from the prior year.
• Enterprise Value climbed to -$818.6 million in Q1 2026 per CYTK's latest filing, from -$882.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$539.6 million in Q3 2023 and bottomed at -$1.1 billion in Q4 2024.
• Historically, Enterprise Value has averaged -$791.7 million across 5 years, with a median of -$818.6 million in 2026.
• Annual changes were most pronounced in 2023 — Enterprise Value jumped 37.81% — and 2024, when it sank 87.55%.
• Cytokinetics' Enterprise Value stood at -$784.2 million in 2022, then grew by 21.55% to -$615.2 million in 2023, then sank by 74.97% to -$1.1 billion in 2024, then rose by 18.04% to -$882.2 million in 2025, then increased by 7.22% to -$818.6 million in 2026.
• Business Quant data shows CYTK's Enterprise Value at -$818.6 million in Q1 2026, -$882.2 million in Q4 2025, and -$962.5 million in Q3 2025.